Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
I want a tricorder,” Alex Wiltschko tells me over email. Wiltschko, the founder of the AI company Osmo, is referring to the handheld device used by the Enterprise’s crew in ...